Connect with us

Technology

Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand

Published

on

A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan’s veterinary product

HERZLIYA, Israel and CALGARY, AB, Nov. 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, announced that it has taken the strategic decision to focus its development resources on advancing its groundbreaking Liposome Platform Technology-Cannabidiol (LPT-CBD), a monthly injectable treatment for chronic pain in both animals and humans. This decision follows encouraging progress with the U.S. Food and Drug Administration (FDA).

 

 

Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan’s non-clinical development plan and Phase I clinical study design for the LPT-CBD’s Investigational New Drug (IND) filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA’s Center for Veterinary Medicine (CVM) with the issuance of an Investigational New Animal Drug (INAD) designation in July.

Given recent U.S. Pet industry reports and data released by the American Pet Products Association (APPA) and the National Pet Owners Survey*, Innocan recognizes significant market potential for an injectable treatment for chronic pain in animals:

66% of U.S. households – 87 million homes – own one or more pets, including 58 million with dogs and 40 million with cats.In 2024, U.S. pet industry expenditures are projected to reach US $156 billion, up from USD $147 billion in 2023, with USD $39 billion anticipated for pharmaceutical drugs and veterinary care.

This new data represents a significantly large and growing market for effective veterinary health products like LPT-CBD, Innocan’s monthly injectable drug product. Innocan’s unique technology is comprised of liposomes loaded with CBD for the treatment of chronic pain. LPT-CBD has demonstrated promising results in multiple animal model tests, as previously reported, providing extended pharmacokinetic benefits and effective pain relief lasting up to four weeks.

Following the positive response of the FDA regarding the LPT-CBT product reported in September 2024, as well as the continued progress of the LPT-CBD project and significant addressable market potential for LPT-CBD, Innocan has decided to shift its focus and resources in its pharmaceutical division to the LPT-CBD project, thereby sunsetting its Cannabinoid-Loaded Exosome (CLX) project conducted with Ramot of Tel Aviv University (Ramot) under Prof. Daniel Offen. A suitable notice of termination of its sponsored research agreement dated April 17, 2020 and its research and funding agreement with Ramot dated December 6, 2021 has been sent, concluding this collaboration.

“The latest pet industry reports show that the market potential of the LPT-CBD products in veterinary health is clearly significant,” commented Iris Bincovich, CEO of Innocan. “Our commitment to pioneering solutions for chronic pain in animals aligns with the growing need for effective, compassionate care. By dedicating increased resources to this market, we can expedite our path to market for LPT-CBD and meet the demands of a dynamic and expanding pet care industry.”

* https://www.marketwatch.com/guides/pet-insurance/pet-ownership-statistics/

About Innocan Pharma:

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

For more information: www.innocanpharma.com

Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/innocan-to-direct-full-focus-on-following-positive-fda-engagement-and-significant-potential-market-demand-302301266.html

Continue Reading

Technology

Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video

Published

on

By

SHENZHEN, China, Nov. 1, 2026 /PRNewswire/ — The host-city theme song for APEC China 2026, Meet You Where Wonders Bloom (在奇迹之城遇见你), was produced by the Publicity Department of the CPC Shenzhen Municipal Committee and created by Shenzhen Media Group. Written and composed by He Muyang, Vice Chairman of the Chinese Musicians Association and a Shenzhen-based musician, the song is performed by popular singers Jane Zhang and Joseph Zeng. With its fresh, youthful pop sound, the song tells the stories of ordinary dreamers, weaving together personal aspirations, Shenzhen’s remarkable development, and the broader vision of Asia-Pacific cooperation.

Released alongside the song, the music video goes beyond showcasing Shenzhen’s cityscape to put people at the heart of the story. Through the experiences of people from all walks of life, particularly young people and those from overseas, it captures the energy and appeal of Shenzhen, the City of Miracles, and its warm welcome to the world. Running 4 minutes and 45 seconds, the video features 176 shots filmed across Shenzhen, with more than 100 residents appearing on screen. From location coordination and filming support to bringing participants together, the production was a citywide effort. More than just a music video, it became a shared expression of Shenzhen’s enthusiasm as APEC host city.

From a refreshing melody to a city ready to welcome the world, Shenzhen is embracing its role as APEC host with openness and inclusiveness, extending a warm invitation to guests from near and far to gather in Shenzhen.

View original content to download multimedia:https://www.prnewswire.com/news-releases/shenzhen-unveils-apec-china-2026-host-city-theme-song-and-music-video-302925715.html

SOURCE Shenzhen Media Group

Continue Reading

Technology

Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video

Published

on

By

SHENZHEN, China, Nov. 1, 2026 /PRNewswire/ — The host-city theme song for APEC China 2026, Meet You Where Wonders Bloom (在奇迹之城遇见你), was produced by the Publicity Department of the CPC Shenzhen Municipal Committee and created by Shenzhen Media Group. Written and composed by He Muyang, Vice Chairman of the Chinese Musicians Association and a Shenzhen-based musician, the song is performed by popular singers Jane Zhang and Joseph Zeng. With its fresh, youthful pop sound, the song tells the stories of ordinary dreamers, weaving together personal aspirations, Shenzhen’s remarkable development, and the broader vision of Asia-Pacific cooperation.

Released alongside the song, the music video goes beyond showcasing Shenzhen’s cityscape to put people at the heart of the story. Through the experiences of people from all walks of life, particularly young people and those from overseas, it captures the energy and appeal of Shenzhen, the City of Miracles, and its warm welcome to the world. Running 4 minutes and 45 seconds, the video features 176 shots filmed across Shenzhen, with more than 100 residents appearing on screen. From location coordination and filming support to bringing participants together, the production was a citywide effort. More than just a music video, it became a shared expression of Shenzhen’s enthusiasm as APEC host city.

From a refreshing melody to a city ready to welcome the world, Shenzhen is embracing its role as APEC host with openness and inclusiveness, extending a warm invitation to guests from near and far to gather in Shenzhen.

View original content to download multimedia:https://www.prnewswire.com/news-releases/shenzhen-unveils-apec-china-2026-host-city-theme-song-and-music-video-302925715.html

SOURCE Shenzhen Media Group

Continue Reading

Technology

Context Labs AI Distillery™ Lets Enterprises Run Sovereign AI on Data They Own

Published

on

By

Company launches the Context Engine for trusted sovereign AI, which packages an enterprise’s own data with verified lineage for use with the frontier or open-weight model the enterprise chooses.

ABU DHABI, United Arab Emirates, Nov. 1, 2026 /PRNewswire/ — Context Labs B.V. (“Context Labs”), the AI Data Infrastructure company, today launched the Context Labs AI Distillery™, the Context Engine for trusted sovereign AI. The AI Distillery converts an enterprise’s operational and business data into a governed Context Package that the enterprise owns, creating their own protected competitive moat. Every answer an AI model draws from the package is traced to its source records, and the package works with the frontier or open weight model the customer chooses, inside the customer’s own environment.

Analysts have quantified the obstacle to scaling enterprise AI. Gartner predicts that through 2026 organizations will abandon 60% of AI projects unsupported by AI-ready data, and that over 40% of agentic AI projects will be canceled by the end of 2027. McKinsey reports that eight in ten companies name data limitations as the barrier to scaling AI agents. Gartner has also described what enterprises now need: software that lets teams construct, govern and deliver semantically organized knowledge to AI agents, built on ontologies and knowledge graphs.

 The Context Labs AI Distillery™ is designed around six outcomes:

Own your IP. An enterprise’s knowledge, know-how and operating context stay inside a Context Package that only it controls and are not used to train third-party AI models.

Own your AI. The intelligence employees create in everyday use accrues to the enterprise, not to a model provider, and grows with every interaction.

Trusted, provable answers. Every output carries its data lineage and decision provenance, so answers can be verified, audited, and defended.

Build, protect and scale a proprietary competitive asset. The Context Package captures how the enterprise describes and runs its operations, starting with one facility and extending to others without rebuilding.

Sovereign by design. The AI Distillery runs inside the customer’s own data center or chosen cloud, so data stays where the customer decides.

Freedom of model choice, at lower cost. Customers can use any frontier or open-weight model and switch models without rebuilding the Context Package. Precise, verified context reduces the tokens each query uses.

The AI Distillery works in three steps: distill, package, and prove. It maps an enterprise’s structured and unstructured data to industry-specific ontologies, stores the result in a Context Package with cryptographic provenance, and checks answers against the company’s own records before any model goes into production. Work that has typically required teams of specialist engineers becomes a guided, governed workflow.

Context Agents and the Semantic Context Tunnel. Context Agents answer operational, commercial and compliance questions from the enterprise’s Context Package, with every figure traced to its source. The Semantic Context Tunnel brings the same context into the AI assistant employees already use. Both work within the access controls the enterprise sets.

“Models come and go. An enterprise’s context should not,” said Dan Harple, Founder, Chairman and CEO of Context Labs. “Frontier models will keep improving, but they do not supply governance, provenance or trust, and they should not absorb the knowledge that makes a company competitive. The AI Distillery gives enterprises a moat they own: their own context, proven and protected, working with whichever model they choose. That is how our customers own their IP and own their AI.”

At ADIPEC 2026, Context Labs is demonstrating the AI Distillery on energy-sector use cases, in which a Context Agent answers operational questions with every figure traced to the underlying plant records. Context Labs is located Arab Development Group stand, Stand #5240, Hall 5 and in the Dell AI Factory with NVIDIA, AI Zone, Hall 13.

Availability. The Context Labs AI Distillery™ is available now through the Microsoft Marketplace. Each enterprise license includes an industry starter kit to accelerate time to value. Companies can request a briefing or technical working session at contextlabs.com/distillery.

About Context Labs B.V.

Context Labs is an AI Data Infrastructure company delivering the Context Engine for Trusted and Secure Sovereign AI. Its platform turns complex, fragmented operational, engineering and enterprise data into continuously verified, auditable information that AI systems, people and markets can trust. Built on an extensible library of industry-specific ontologies that map to established standards published by ISO and other standards bodies, the platform is deployable across sectors, with use-case applications delivering decision-ready intelligence on a common foundation. The Context Labs AI Distillery™ lets enterprises run sovereign AI inside their own data centers, so they own their IP and own their AI. Formed out of MIT research and led by a team that helped drive the at-scale growth of the Internet, Context Labs has offices in Amsterdam, Cambridge (Mass.), Houston and Abu Dhabi. Learn more at www.contextlabs.com.

Media contact
press@contextlabs.com | 1-617-902-0932 | contextlabs.com/resources

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/context-labs-ai-distillery-lets-enterprises-run-sovereign-ai-on-data-they-own-302925657.html

Continue Reading

Trending